Rare Benign Lesion of Peins

• ClinicalTrials.gov Identifier: NCT04725292
• Recruitment Status: Completed
• First Posted: January 26, 2021
• Last Update Posted: January 26, 2021
• Sponsor: Assiut University
• Information provided by (Responsible Party): Abdelrahman Mohamed Abdelkader, Assiut University

Study Description

Brief Summary:

PEKMB was first named and described by Lortat-Jacob & Civatte in 1961 and by Bart & Kopf later. This rare condition is mostly reported in elderly males. The keratotic scales is usually micaceous and resembles psoriasis. Most patients are above 50 years of age and are circumcised later in life, but also reported in younger age group. This mica like scales contains keratin which gets dissolved in 10% potassium hydroxide solution. Disease progression may lead to phimosis. Differential diagnosis of this disease entity include moniliasis, wart, psoriasis ,penile horn, circinate balanitis, erythroplasia of Queyrat, squamous cell epithelioma and verrucous carcinoma. It is primarily a benign entity, it is capable of invasiveness. Bart and Kopf considered it to be in intermediate stage between benign hyperplasia and squamous cell carcinoma. However, the histological spectrum can range from hypertrophic-hyperplastic penile dystrophy to verrucous carcinoma. Fibro sarcoma has been reported developing in a same patient. Etiology is unclear. Despite search for a viral agent, Human Papilloma Virus (HPV) has not been demonstrated and its role in pathogenesis or its transformation to verrucous carcinoma has been proved. The treatment of PEKMB should be conservative when there is no histological evidence of malignancy. All such patients should be followed up. Treatment choices include potent topical steroids, topical 5% 5-flurouracil cream1, 2, cryotherapy, radiotherapy and shaving biopsy plus electro coagulation. When frank malignancy is observed, excision with wide margin is the rule.

Condition or disease
Skin Diseases; Penile Diseases

Study Design

• Study Type: Observational
• Actual Enrollment: 1 participants
• Observational Model: Other
• Time Perspective: Other
• Official Title: Pseudoepitheliomatous Hyperplasia of the Penis a Very Rare Disease in Egypt
• Actual Study Start Date: January 12, 2021
• Actual Primary Completion Date: January 12, 2021
• Actual Study Completion Date: January 12, 2021

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. improvement of the skin lesion [ Time Frame: 1 month after treatment ]
   drugs will be given to patient then the effect ,either improvement or worsening will be noticied
2. improvement of associated lesion [ Time Frame: 1 month after drug given ]
   patient complained of difficulty and burning micturition which will be seen after treatment

Eligibility Criteria

• Ages Eligible for Study: 35 Years to 50 Years (Adult)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Gender Eligibility Description: case report
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

male healthy married

Criteria

Inclusion Criteria:

• 40 years
• failed medical treatment

Exclusion Criteria:

• psoriasis
• allergy
• trauma

Contacts and Locations

Locations

Egypt

Assuit Medical School

Assiut, Assuit, Egypt, 71621

Sponsors and Collaborators

Assiut University

More Information

• Responsible Party: Abdelrahman Mohamed Abdelkader, chief resident of urology, Assiut University
• ClinicalTrials.gov Identifier: NCT04725292
• Other Study ID Numbers: penis skin lesion
• First Posted: January 26, 2021
• Last Update Posted: January 26, 2021
• Last Verified: January 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Penile Diseases; Skin Diseases